Accounts Payable

9 Months Ended

Sep. 30, 2013

Accounts Payable Disclosure [Abstract]

Accounts Payable

4.Accounts Payable

As of September 30, 2013, Current Liabilities included accounts payable of $43,578 comprised primarily of approximate amounts owed to the Company’s drug substance manufacturer totaling $9,900, $8,100 for consultants and advisors to the Company, $6,900 in services as the Company commenced development of a data management system for clinical trial patient data, $9,300 for legal fees and $9,400 for communications, miscellaneous drug development and clinical trial expense. As of December 31, 2012, Current Liabilities included accounts payable $57,000 and accounts payable related party of $8,582, which amounts were subsequently paid in 2013.